Glenmark to Pay $25 Million to Settle Price Fixing Liabilities

A generic pharmaceutical manufacturer agreed to pay $25 million to resolve its alleged liability under the False Claims Act for conspiring to fix the price of a generic drug, the Justice Department announced Thursday.

From 2013 to 2015, Glenmark Pharmaceuticals paid and received compensation prohibited by the Anti-Kickback Statute through arrangements on price, supply, and allocation of customers with other pharmaceutical manufacturers for a generic drug pravastatin, which is widely used to treat high cholesterol and triglyceride levels, according to the DOJ.

The manufacturer previously entered into a deferred prosecution agreement with the Justice Department’s Antitrust Division to resolve ...